Epigral Ltd

Epigral Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Epigral Ltd

₹ 1,043 1.32%
30 Jan - close price
epigral.com BSE: 543332 NSE: EPIGRAL
About

Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral’s Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure.

In India, Epigral is the first to set up an Epichlorohydrin plant and largest capacity plant of CPVC Resin. Epigral is also a leading manufacturer of Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, Chlorine and Hydrogen.

Key Points

Product Segments
a. Derivatives & Speciality Chemicals (56% in H1 FY25 vs 25% in FY22): [1] [2] The company is the 5th largest producer of Chloromethanes (CMS) in India, its CMS portfolio includes MDC, Chloroform and CTC. It is also 3rd largest producer of Hydrogen Peroxide in India. [3] It also produces specialty chemicals like CPVC Resin, CPVC compound, Epichlorohydrin, Chlorotoluenes Value Chain, etc. [4]

Website BSE NSE
  • Market Cap ₹ 4,500 Cr.
  • Current Price ₹ 1,043
  • High / Low ₹ 2,114 / 996
  • Stock P/E 13.3
  • Book Value ₹ 487
  • Dividend Yield 0.58 %
  • ROCE 25.1 %
  • ROE 22.6 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 24.9%

Cons

  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals

Part of BSE Allcap BSE Commodities Nifty Microcap 250 Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
538 562 455 478 472 525 651 626 645 628 607 587 597
371 408 360 370 349 369 475 448 463 454 443 455 494
Operating Profit 167 155 95 108 123 155 176 178 183 173 163 132 103
OPM % 31% 28% 21% 23% 26% 30% 27% 28% 28% 28% 27% 22% 17%
-0 5 2 1 2 2 2 6 4 4 9 2 6
Interest 21 19 18 21 20 14 14 27 -0 12 23 22 11
Depreciation 31 30 31 32 31 30 33 32 33 34 42 42 43
Profit before tax 114 110 47 56 74 113 131 125 154 131 107 70 55
Tax % 33% 30% 34% 32% 34% 32% 34% 35% 33% 34% -50% 26% 28%
77 77 32 38 49 77 86 81 104 87 161 51 39
EPS in Rs 18.58 18.47 7.58 9.14 11.81 18.60 20.67 19.57 24.02 20.14 37.25 11.87 9.07
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
829 1,551 2,188 1,929 2,550 2,419
567 1,041 1,499 1,448 1,839 1,847
Operating Profit 261 509 689 481 711 572
OPM % 32% 33% 31% 25% 28% 24%
2 4 8 7 16 20
Interest 29 44 66 73 53 68
Depreciation 74 86 109 124 133 161
Profit before tax 161 383 522 291 541 363
Tax % 37% 34% 32% 33% 34%
101 253 353 196 358 338
EPS in Rs 24.48 60.84 85.03 47.14 82.91 78.33
Dividend Payout % 0% 0% 6% 11% 7%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 18%
TTM: -1%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 12%
TTM: -3%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 0%
1 Year: -44%
Return on Equity
10 Years: %
5 Years: 27%
3 Years: 25%
Last Year: 23%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 42 42 42 42 43 43
Reserves 432 684 1,028 1,213 1,861 2,058
753 993 879 964 593 537
222 405 484 576 655 598
Total Liabilities 1,449 2,124 2,432 2,794 3,152 3,236
1,102 1,068 1,804 1,767 2,238 2,176
CWIP 126 589 158 483 64 309
Investments 0 0 21 21 98 45
221 467 450 524 752 707
Total Assets 1,449 2,124 2,432 2,794 3,152 3,236

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
229 284 626 398 441
-197 -455 -437 -401 -262
-32 195 -200 -8 -164
Net Cash Flow 1 24 -11 -11 15

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 52 60 28 34 33
Inventory Days 51 74 69 90 105
Days Payable 69 42 36 63 50
Cash Conversion Cycle 34 92 61 61 88
Working Capital Days -92 -26 -41 -54 26
ROCE % 29% 32% 17% 25%

Shareholding Pattern

Numbers in percentages

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
71.34% 71.37% 71.38% 71.38% 71.49% 71.58% 71.58% 68.94% 68.95% 68.83% 68.83% 68.83%
1.20% 1.16% 1.14% 1.17% 1.36% 1.46% 2.10% 3.01% 3.01% 3.06% 2.71% 2.36%
0.03% 0.04% 0.04% 0.05% 0.02% 0.18% 1.17% 4.31% 4.66% 4.78% 4.93% 5.13%
0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02%
27.39% 27.39% 27.40% 27.37% 27.10% 26.75% 25.12% 23.71% 23.34% 23.30% 23.52% 23.67%
No. of Shareholders 94,77895,83395,74292,95988,87085,76183,17681,69780,87879,95178,60577,562

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls